These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32410009)

  • 21. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
    Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
    Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mismatch repair protein expression of colorectal cancer: a retrospective analysis of 3 428 cases].
    Liu Y; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Zang FL; Qiu ZQ; Sun BC; Sun Y
    Zhonghua Bing Li Xue Za Zhi; 2021 Apr; 50(4):369-375. PubMed ID: 33831997
    [No Abstract]   [Full Text] [Related]  

  • 23. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
    Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
    [No Abstract]   [Full Text] [Related]  

  • 24. MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas.
    Chen W; Pearlman R; Hampel H; Pritchard CC; Markow M; Arnold C; Knight D; Frankel WL
    Hum Pathol; 2020 Feb; 96():104-111. PubMed ID: 31783044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers.
    Kato M; Takano M; Miyamoto M; Sasaki N; Goto T; Tsuda H; Furuya K
    J Gynecol Oncol; 2015 Jan; 26(1):40-5. PubMed ID: 25310854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
    Shia J; Stadler Z; Weiser MR; Rentz M; Gonen M; Tang LH; Vakiani E; Katabi N; Xiong X; Markowitz AJ; Shike M; Guillem J; Klimstra DS
    Am J Surg Pathol; 2011 Mar; 35(3):447-54. PubMed ID: 21297438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
    Chung YS; Woo HY; Lee JY; Park E; Nam EJ; Kim S; Kim SW; Kim YT
    Am J Obstet Gynecol; 2021 Apr; 224(4):370.e1-370.e13. PubMed ID: 33039397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parameters.
    Hashmi AA; Ali R; Hussain ZF; Faridi N; Khan EY; Bakar SMA; Edhi MM; Khan M
    World J Surg Oncol; 2017 Jun; 15(1):116. PubMed ID: 28651545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
    Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
    Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
    Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
    Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mismatch Repair Protein Deficiency Does Not Affect Disease Free Survival in Type I Endometrial Carcinoma.
    Angelina YA; Tjokroprawiro BA; Sandhika W
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3229-3234. PubMed ID: 37774076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma.
    Vasan K; Satgunaseelan L; Anand S; Asher R; Selinger C; Low TH; Palme CE; Clark JR; Gupta R
    Pathology; 2019 Dec; 51(7):688-695. PubMed ID: 31630878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer.
    Chu MM; Liu SS; Tam KF; Ip PP; Cheung AN; Ngan HY
    Int J Gynecol Pathol; 2015 Sep; 34(5):403-10. PubMed ID: 26262451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.
    Haraldsdottir S; Roth R; Pearlman R; Hampel H; Arnold CA; Frankel WL
    Fam Cancer; 2016 Apr; 15(2):253-60. PubMed ID: 26666765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lynch syndrome identification in a Brazilian cohort of endometrial cancer screened by a universal approach.
    Rosa RCA; Santis JO; Teixeira LA; Molfetta GA; Dos Santos JTT; Ribeiro VDS; Chahud F; Ribeiro-Silva A; Brunaldi MO; Silva WA; Ferraz VEF
    Gynecol Oncol; 2020 Oct; 159(1):229-238. PubMed ID: 32694065
    [TBL] [Abstract][Full Text] [Related]  

    Ivanova K; Stoyanov S; Vlaykova T; Gulubova M
    Akush Ginekol (Sofiia); 2016; 55(5):21-28. PubMed ID: 29790711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two versus four immunostains for Lynch syndrome screening in endometrial carcinoma.
    Niu BT; Hammond RFL; Leen SLS; Gilks CB; Singh N
    Histopathology; 2019 Sep; 75(3):442-445. PubMed ID: 31077605
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.
    Long Q; Peng Y; Tang Z; Wu C
    Int J Clin Exp Pathol; 2014; 7(10):7297-303. PubMed ID: 25400828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.